<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NAPHCON- naphazoline hydrochlorideÂ solutionÂ </strong><br>Alcon<br></p></div>
<h1>NAPHCONÂ® FORTE<br>(naphazoline hydrochloride<br>ophthalmic solution USP), 0.1%</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1> DESCRIPTION</h1>
<p class="First">NAPHCONÂ® FORTE (Naphazoline Hydrochloride Ophthalmic Solution USP), 0.1% is a sterile preparation. Naphazoline HCl, an ocular vasoconstrictor, is an imidazoline derivative sympathomimetic amine. It occurs as a white, odorless crystalline powder having a bitter taste and is freely soluble in water and in alcohol. The active ingredient is represented by the structural formula:</p>
<p><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9951c888-4b6a-4c76-a9c1-dc3a0c777191&amp;name=naphconforte-01.jpg"></p>
<p>C<span class="Sub">14</span>H<span class="Sub">14</span>N<span class="Sub">2</span>HCl</p>
<p>MW=246.74</p>
<p>Chemical name:</p>
<p>2-(1-naphthylmethyl)-2-imidazoline monohydrochloride</p>
<p><span class="Bold">Each mL contains: Active: </span>Naphazoline Hydrochloride 0.1%. <span class="Bold">Preservative: </span>Benzalkonium Chloride 0.01%. <span class="Bold">Inactives: </span>Boric Acid, Sodium Chloride, Potassium Chloride, Edetate Disodium, Sodium Carbonate and/or Hydrochloric Acid (to adjust pH), Purified Water. DM-00</p>
<p>The solution has a pH of 5.5 to 7.0.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1> CLINICAL PHARMACOLOGY</h1>
<p class="First">Naphazoline constricts the vascular system of the conjunctiva. It is presumed that this effect is due to direct stimulation action of the drug upon the alpha adrenergic receptors in the arterioles of the conjunctiva resulting in decreased <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival congestion</span>. Naphazoline belongs to the imidazoline class of sympathomimetics.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1> INDICATIONS AND USAGE</h1>
<p class="First">NAPHCONÂ® FORTE (Naphazoline Hydrochloride Ophthalmic Solution USP), 0.1% is indicated for use as a topical ocular vasoconstrictor.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1> CONTRAINDICATIONS</h1>
<p class="First">Contraindicated in the presence of an anatomically narrow angle or in narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or in persons who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of this preparation.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1> WARNINGS</h1>
<p class="First">NOT FOR INJECTION â€“ FOR OPHTHALMIC USE ONLY. Patients under therapy with MAO inhibitors may experience a severe <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span> if given a sympathomimetic drug. Use in children, especially infants, may result in <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> leading to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and marked reduction in body temperature.</p>
<p>Remove contact lenses before using.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1> PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2> General</h2>
<p class="First">For topical ophthalmic use only. Use with caution in the presence of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, cardiovascular abnormalities, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> (<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>), <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or injury.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2> Information for Patients</h2>
<p class="First">Patients should be advised to discontinue the drug and consult a physician if relief is not obtained within 48 hours of therapy, if irritation, blurring or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> persists or increases, or if symptoms of systemic absorption occur, i.e., <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, decrease in body temperature, or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>.</p>
<p>To prevent contaminating the dropper tip and solution, do not touch the eyelids or the surrounding area with the dropper tip of the bottle. If solution changes color or becomes cloudy, do not use.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.3"></a><p></p>
<h2> Drug Interactions</h2>
<p class="First">Concurrent use of maprotiline or tricyclic antidepressants and naphazoline may potentiate the pressor effect of naphazoline. Patients under therapy with MAO inhibitors may experience a severe <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span> if given a sympathomimetic drug. (See WARNINGS.)</p>
</div>
<div class="Section">
<a name="section-7.4"></a><p></p>
<h2> Pregnancy Category C</h2>
<p class="First">Animal reproduction studies have not been conducted with naphazoline. It is also not known whether naphazoline can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Naphazoline should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.5"></a><p></p>
<h2> Nursing Mothers</h2>
<p class="First">It is not known whether naphazoline is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when naphazoline is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.6"></a><p></p>
<h2> Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established. See â€œWARNINGSâ€? and â€œCONTRAINDICATIONS.â€?</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1> ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">Ocular: </span><span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">Mydriasis</span>, increased <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, irritation, <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, blurring, punctuate <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>.</p>
<p><span class="Bold">Systemic: </span><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, cardiac irregularities, and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1> DOSAGE AND ADMINISTRATION</h1>
<p class="First">Instill one or two drops in the conjunctival sac(s) every three to four hours as needed.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1> HOW SUPPLIED</h1>
<p class="First">NAPHCONÂ® FORTE (Naphazoline Hydrochloride Ophthalmic Solution USP), 0.1% is available in 15 mL in DROP-TAINERÂ® dispenser.</p>
<p><span class="Bold">NDC </span>0998-0079-15.</p>
<p><span class="Bold">Storage: </span>Store at 8Â° - 27Â°C (46Â° - 80Â°F).</p>
<p><span class="Bold">Caution: </span>Federal ( USA) law prohibits dispensing without prescription.</p>
<p><span class="Bold">ALCON ( Puerto Rico) INC.</span><br>Humacao, Puerto Rico 00791  USA</p>
<p>
					Printed in  USA</p>
<p>September 1996</p>
<p><span class="Bold">236185</span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NAPHCONÂ 		
					</strong><br><span class="contentTableReg">naphazoline hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0998-0079</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>naphazoline hydrochloride</strong> (naphazoline) </td>
<td class="formItem"></td>
<td class="formItem">1Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>benzalkonium chloride</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>boric acid</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>potassium chloride</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium carbonate and/or hydrochloric acid</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0998-0079-15</td>
<td class="formItem">15 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Alcon</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>B7C0D195-7834-185A-E40C-7632DD80DB06</div>
<div>Set id: 9951c888-4b6a-4c76-a9c1-dc3a0c777191</div>
<div>Version: 1</div>
<div>Effective Time: 20060420</div>
</div>
</div>Â <div class="DistributorName">Alcon</div></p>
</body></html>
